Topic: Technology Licensing

Latest content

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market

26 August 2021

Meet the people who make the global patent transactions market tick

The Long Read: Grounded at home and facing an uncertain business environment, IP business leaders still found ample opportunity to make innovative deals during the covid pandemic. Today, we name the individuals sitting in places 40 down to 11 in this year's IAM Market Makers ranking

25 August 2021

Maxell deploys recently-acquired patents in new smart TV litigation

Japanese battery maker has made Vizio the latest target in its IP monetisation effort

24 August 2021

Brazil on the cusp of passing landmark compulsory technology transfer law

Life sciences innovators may be compelled to hand over trade secrets, data and biological materials under legislation that now only requires President Bolsonaro’s signature to become law

19 August 2021

Dolby hit with South Korean fine for breach of FRAND obligations

Country’s competition authority imposes 270 million won penalty on the company for abusing the bargaining position its ownership of SEPs created

18 August 2021

A $300 million damages award against Apple shows why equating all NPEs with patent trolls is so wrong

Yesterday’s decision in favour of PanOptis by an Eastern District of Texas jury was the consequence of significant investments made by the firm over many years

14 August 2021

Japan ministry study group says new rules needed to guide SEP negotiation process

But the METI report stops short of concrete policy recommendations, saying government should continue to weigh issues faced by Japanese industry

13 August 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

US legislators have anti-competitive pharma IP strategies in their sights

There is now momentum behind several proposed pieces of legislation with implications for life sciences patents

06 August 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams

05 August 2021

Get unlimited access to all IAM content